A preclinical evaluation and first-in-man case for transcatheter edge-to-edge mitral valve repair using PulveClip®transcatheter repair device  

作　　者：Gang-Jun ZONG Jie-Wen DENG Ke-Yu CHEN Hua WANG Fei-Fei DONG Xing-Hua SHAN Jia-Feng WANG Ni ZHU Fei LUO Peng-Fei DAI Zhi-Fu GUO Yong-Wen QIN Yuan BAI 

机构地区：[1]Department of Cardiology,The 904th Hospital of Joint Logistic Support Force of PLA,Jiangsu,China [2]Department of Cardiology,Shanghai Changhai Hospital,Navy Military Medical University,Shanghai,China [3]Department of Anesthesiology,Shanghai Changhai Hospital,Navy Military Medical University,Shanghai,China

出　　处：《Journal of Geriatric Cardiology》2025年第2期265-269,共5页老年心脏病学杂志(英文版)

基　　金：supported by the Cultivation of Scientific Research Project of Changhai Hospital,Shanghai,China(No.2021JCMS20);Major Topics of the Health Commission of Jiangsu Province(ZD2021020).

摘　　要：The prevalence of mitral regurgitation(MR)is increasingly worldwide as a consequence of improved survival and ischemic heart disease.Severe MR is associated with worse prognosis,independent of left ventricular function and associated comorbidities.[1-3]Although surgical valve repair or replacement remains the standard treatment for patients with chronic MR,up to 50%of MR patients with symptomatic MR are not referred for surgery,mainly because of multiple comorbid conditions resulting in high surgical risk.[4]There is,therefore,a clear need for less invasive approaches for this patient group.

关 键 词：MITRAL TRANSCATHETER PROGNOSIS 

分 类 号：R73[医药卫生—肿瘤]